vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report released on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Price Performance

Shares of vTv Therapeutics stock opened at $20.20 on Friday. vTv Therapeutics has a 1 year low of $8.10 and a 1 year high of $30.99. The business has a 50-day moving average of $15.68 and a two-hundred day moving average of $15.09. The company has a market capitalization of $64.44 million, a P/E ratio of -4.46 and a beta of 0.73.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of vTv Therapeutics during the fourth quarter worth about $25,000. Geode Capital Management LLC grew its holdings in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,327 shares in the last quarter. Finally, FMR LLC bought a new position in shares of vTv Therapeutics during the third quarter worth about $2,402,000. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.